Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications.

Rakesh C Kukreja1, Fadi Salloum, Anindita Das

  • 1Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, P.O. Box 980281, 1101 East Mashall Street, Room 7-046, Richmond, VA 23298-0281, USA. rakesh@hsc.vcu.edu

Vascular Pharmacology
|June 1, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving Statin Prescribing for People Living With HIV: A Quality Improvement Initiative.

JACC. Case reports·2026
Same author

Surface-Induced Donor-Acceptor Charge-Transfer Interaction in Crystallization-Driven Two-Dimensional Assembly of Poly(L-Lactide) and Its Impact on Piezoelectric Performance.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

From Guidance to Practice: Understanding the 2026 AUA/ASTRO Clinically Localized Prostate Cancer Guideline Amendment.

The Journal of urology·2026
Same author

Identifying clinician-reported medication "Failure modes" in the nursing home setting that are amenable to active monitoring.

Research in social & administrative pharmacy : RSAP·2026
Same author

Addressing challenging impurities in fusion proteins: A comprehensive review and cost-effective strategy for HCP and low molecular weight species control.

Biotechnology progress·2026
Same author

Federated Meta-Analysis of HEART Score Performance for Emergency Department Chest Pain.

Academic emergency medicine : official journal of the Society for Academic Emergency Medicine·2026

Sildenafil, a phosphodiesterase type-5 (PDE5) inhibitor, demonstrates cardioprotective effects against heart injury in animal studies. This drug may offer clinical benefits for treating heart conditions and improving patient outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Molecular Biology

Background:

  • Sildenafil is a phosphodiesterase type-5 (PDE5) inhibitor initially developed for erectile dysfunction.
  • Experimental data suggest sildenafil possesses cardioprotective properties, mimicking preconditioning effects against ischemia/reperfusion injury.

Purpose of the Study:

  • To investigate the cardioprotective mechanisms of sildenafil.
  • To explore the potential clinical applications of sildenafil beyond erectile dysfunction, including cardiovascular protection.

Main Methods:

  • Animal models of ischemia/reperfusion injury.
  • Mechanistic studies involving nitric oxide (NO) pathways, protein kinase C/ERK signaling, and mitochondrial ATP-sensitive potassium channels.
  • Assessment of cardiomyocyte cell death (necrosis and apoptosis) and Bcl2/Bax ratio.

Related Experiment Videos

Main Results:

  • Sildenafil demonstrated a preconditioning-like cardioprotective effect in animal hearts.
  • Mechanisms involve NO generation, protein kinase C/ERK activation, and mitochondrial channel opening.
  • Sildenafil attenuated cardiomyocyte necrosis and apoptosis, increasing the Bcl2/Bax ratio via NO signaling.

Conclusions:

  • Sildenafil exhibits significant cardioprotective effects through multiple molecular pathways.
  • Emerging evidence suggests potential clinical uses for pulmonary arterial hypertension and endothelial dysfunction.
  • Further clinical studies are warranted to translate these findings into patient care for ischemic heart conditions.